Search

Pt-free composite counter electrode (CE) composed of La2O3 was successfully synthesized by a simple pyrolysis of Lanthanum acetate hydrate (La(CH3COO)3·xH2O) in a high-temperature solid phase. Furthermore, three proportion composite catalysts of La2O3@MWCNTs based on La2O3 and multiwall carbon nanotubes (MWCNTs) were prepared and characterized as Pt-free catalysts for CE in dye-sensitized solar cells (DSSCs). The morphology and structure of La2O3@MWCNT composites were determined by scanning electron microscopy and X-ray diffraction. The electrochemical performance of La2O3@MWCNT composite catalysts for CEs was determined by photocurrent-voltage measurements, cyclic voltammetry, electrochemical impedance spectroscopy, and Tafel polarization. The experimental results showed that the power conversion efficiencies of 5.20, 5.12, and 4.70% were obtained for La2O3: MWCNTs with mass ratios of 5:1, 3:1, and 1:1 as counter electrode towards the reduction of I3−/I− ions respectively in the encapsulation of DSSC batteries, which were higher than that of MWCNTs (3.94%) and La2O3 (0.77%) electrode under the similar conditions. The enhanced electrode performance was attributed to relatively larger surface area and higher conductivity of La2O3@MWCNT composite catalysts. [ABSTRACT FROM AUTHOR]

Background: PCSK9 MaB (Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor) may reduce the occurrence of major adverse cardiovascular events (MACEs) in patients diagnosed with acute coronary syndrome (ACS). In this meta-analysis, we conducted a thorough compilation of evidence from established clinical studies to evaluate PCSK9 MaB's capacity to control blood lipid levels and prevent MACEs in ACS patients., Methods: We conducted searches on Pubmed, Embase, the Cochrane Library, and Web of Science to identify relevant articles. Data from ACS patients were extracted using a standardized format for aggregating data. We calculated the risk ratio (RR) for MACE and assessed changes in blood lipid parameters. All statistical analyses were performed using RevMan., Results: 11 articles representing 5 trials were included in our systematic review and meta-analysis. When compared to a placebo, PCSK9 MaB significantly reduced the risk of MACEs ( I 2 = 0%, p = 0.63, RR [95% CI] = 0.88 [0.81, 0.97], p < 0.01) and the recurrence rate of ACS ( I 2 = 45%, p = 0.18, RR [95% CI] = 0.89 [0.83, 0.95], p < 0.01). Additionally, PCSK9 MaB notably reduced low-density lipoprotein cholesterol (LDL-C) levels (SMD [95% CI] = -2.12 [-2.32, -1.92], p < 0.01) and Apolipoprotein B (ApoB) levels (SMD [95% CI] = -1.83 [-2.48, -1.18], p < 0.01). Importantly, there were no significant differences in adverse reactions between the PCSK9 MaB group and the control group., Conclusions: PCSK9 MaB, whether used as a standalone treatment or in combination with other therapies, can effectively inhibit PCSK9. It substantially lowers key blood lipid parameters, including low-density lipoprotein (LDL), ApoB, and triglycerides, all without giving rise to notable safety concerns., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2024 The Author(s). Published by IMR Press.)